Right to Grant. Subject to Section 3.3 hereof, and certain rights held by Isis Pharmaceuticals in patent application number [*], Emory hereby represents that it has not granted to any third party, and no third party holds, any option, license, sublicense or similar right relating to the use of the Licensed Subject Matter within the Field. Emory further represents that it has the right to grant the license granted hereunder to the Licensed Patents and Licensed Technology.
Appears in 2 contracts
Sources: License Agreement (Atherogenics Inc), License Agreement (Atherogenics Inc)